Iruplinalkib (WX-0593) is a Chinese innovative ALK/ROS1-TKI, which has shown promising anticancer activity and favorable safety profile among patients with advanced NSCLC harbouring ALK or ROS1 rearrangement. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.